Nanobiotix Schedules Investor Roadshows Amidst Nasdaq Listing
Event summary
- Nanobiotix will participate in four investor conferences in March 2026.
- Presentations will occur at TD Cowen’s Health Care Conference (March 4th), UBS Biotech Summit Miami, Jefferies Biotech on the Beach Summit, and Leerink’s Global Healthcare Conference (March 11th).
- CEO Laurent Levy and CFO Bart van Rhijn will represent Nanobiotix at all listed events.
- The company is listed on both Euronext Paris and the Nasdaq Global Select Market.
The big picture
Nanobiotix’s aggressive conference schedule highlights the ongoing need for biotech firms to engage actively with investors, especially those with dual listings. The company’s valuation is sensitive to clinical trial data and regulatory approvals, making these presentations key moments for shaping market perception. The choice of conferences, featuring major investment banks, indicates a targeted effort to reach institutional investors.
What we're watching
- Capital Access
- The frequency of investor presentations suggests Nanobiotix is actively seeking to manage its stock price and potentially raise capital, particularly given its dual listing on Euronext and Nasdaq.
- Pipeline Progress
- The content of the fireside chats will be crucial; investors will scrutinize any updates on clinical trial progress and regulatory pathways for Nanobiotix's nanotherapeutic platforms.
- Market Sentiment
- The reception at these conferences will likely reflect broader investor sentiment towards late-stage biotechnology companies, which can be heavily influenced by macroeconomic factors and competitor activity.
Related topics